Systemic Sclerosis cohort study of 506 SSc pts with saw 5.3 with Degos-like lesions (89% in fingers). Degos lesions more assoc w/ diffuseSSc & acro-osteolysis, digital ulcers, and calcinosis (but not renal crisis, ILD, or pulmonary HTN https://t.co/eCumzZvEmO https://t.co/B41NLt4RYF

Multicenter study of 80 AOSD & 60 controls used to develop AOSD criteria: - 3 pts rash - 3pts fever ≥ 39C - 2 pts pharyngitis - 2 pts arthritis - 2 pts NLR ≥ 4 - 1 pt glycosyl ferritin ≤ 20% 7 pts = Dx (sens 92.5%) vs Yamaguchi(79%), Fautrel (76%) https://t.co/UvtSABRs8s https://t.co/LzqWdyaj8h

Full read, solid review of Diagnosis and management of autoimmune hepatitis from BMJ https://t.co/mc1ozL6CG8 https://t.co/xQkX7WpETv

Pregnancy & RA: metanalysis of 9 studies, 12K RA pts met vs 10 million controls. RA preg have more maternal complications (C sect OR 1.55; preeclampsia OR, 1.6; preterm OR, 1.8) & neonatal probs (low gestat wt, ICU OR 1.34, & stillbirths OR, 1.99). https://t.co/1hA0zGsDtk https://t.co/awaV07GbEv

Join us on 3/18 and 3/19 in Dallas, Texas, or virtually for RheumNow Live! RheumNow Live is unlike any meeting you've ever attended. Here's why: -Inspired Education -The Audience Matters - A meeting designed to change your mind and practice. https://t.co/wWjsjWATdv https://t.co/Rd7O3Yhpw3

Early ph II Pilot trial of 30 Systemic Sclerosis Pts using a new antifibrotic FT011 400mg vs 200mg v PBO x 12 wks showed CRISS score improved by 60% (400mg; (p=0.02 ) or 20% (200mg) at 12wks. An OL extension is planned for 9 mos @400 mg/d. https://t.co/ZU5wGXMDMC https://t.co/9kp20kfuCn

β-damascone, a major aroma from rose, was shown in animal models to dendritic cell -mediated immune functions, thusly demonstrating anti-inflammatory properties https://t.co/0w2b2dflkM https://t.co/zz0l7DJSY4

Know your numbers!! Dr. Jack Cush reviews the news, journal articles and the numbers, from the past week on https://t.co/V10S4oVFsv. https://t.co/xU0Ti4wwpq https://t.co/iQId9IDqHc

Serious Infection Risk in Pediatric Psoriasis with Ustekinumab, Etanercept, or MTX This comparative analysis looks at the risk of SIE requiring hospitalization in pediatric PSO patients treated with ustekinumab, etanercept, or MTX prior to 2016. https://t.co/kR14nrZzCo https://t.co/ccFJcO0eAj

The FDA has added a new indication to the oral JAK inhibitor Cibinqo (abrocitinib) - now approved to treat atopic dermatitis in adolescents 12 to under 18 years old. (Approval is based on a phase 3 JADE TEEN trial. https://t.co/DsQj3BfPmZ https://t.co/0bpb2FAwpg